

#3

1646

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 02307K-026726US
Client Reference No.: 88-001-A Con

#3



Assistant Commissioner for Patents
Washington, D.C. 20231

**COPY OF PAPERS
ORIGINALLY FILED**

On 04/01/02

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]
Brad J. Loos

RECEIVED

APR 17 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lewis T Williams et al.

Application No.: 10/027,400

Filed: December 19, 2001

For: HUMAN PLATLET-DERIVED
GROWTH FACTOR RECEPTORS

Examiner: Unassigned

Art Unit: 1646

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 08/461,917, filed June 5, 1995 (Attorney Docket No. 02307K-026724US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Lewis T Williams et al.
Application No.: 10/027,400

PATENT

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Andrew T. Serafini
Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
ATS:bjl/ao

PA 3211343 v1

**COPY OF PAPERS
ORIGINALLY FILED**

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **6**

Complete if Known

Application Number	10/027,400
Filing Date	December 19, 2001
First Named Inventor	Lewis Thomas Williams
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	02307K-026726US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	4,766,073		Murray et al.	08/1988	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AB		0 325 224		EPO	07/1989		
	AC		0 327 369		EPO	08/1989		
	AD		90/10013		PCT	09/1990		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AE	ANDERSON et al., "Binding of SH2 Domains of Phospholipase Cy1, GAP, and Src to Activated Growth Factor Receptors," <i>Science</i> , 250:979-982 (1990).	
	AF	BELL, et al., "Effect of Platelet Factors on Migration of Cultured Bovine Aortic Endothelial and Smooth Muscle Cells," <i>Circulation Research</i> , 65(4):1057-1065.	
	AG	BETSHOLTZ et al., "Coexpression of a PDGF-like Growth Factor and PDGF Receptor: in Human Osteosarcoma Cell Line: Implications for Autocrine Receptor Activation," <i>Cell</i> , 39:447-457 (1984).	
	AH	BISHAYEE et al., "Ligand-induced Dimerization of the Platelet-derived Growth Factor Receptor," <i>J. Biol. Chem.</i> , 264(20):11699-11705 (1989).	
	AI	CLAESSON-WELSH et al., "cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF Molecules," <i>Mol. Cell. Biol.</i> , 8(8):3476-3486 (1988).	
	AJ	CLAESSON-WELSH et al., "cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor," <i>Proc. Nat'l Acad. Sci. USA</i> , 86:4917-4921 (1989).	
	AK	COUGHLIN et al., "Role of Phosphatidylinositol Kinase in PDGF Receptor Signal Transduction," <i>Science</i> , 243:1191-1194 (1989).	
	AL	DANIEL et al., "Purification of the platelet-derived growth factor receptor by using an anti-phosphotyrosine antibody," <i>Proc. Nat'l Acad. Sci. USA</i> , 82:2684-2687 (1985).	
	AM	DANIEL et al., "Biosynthetic and Glycosylation Studies of Cell Surface Platelet Derived Growth Factor Receptors," <i>J. Biol. Chem.</i> , 262(20):9778-9784 (1987).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3211343 v1

RECEIVED

APR 17 2002

TECH CENTER 1600/2900



Please type a plus sign (+) inside this box

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

Application Number	10/027,400
Filing Date	December 19, 2001
First Named Inventor	Lewis Thomas Williams
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	02307K-026726US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AN				ESCOBEDO et al., "Role of Tyrosine Kinase and Membrane-Spanning Domains in Signal Transduction by the Platelet-Derived Growth Factor Receptor," <u>Mol. Cell Biol.</u> , 8(12):5126-5131 (1988).			
	AO				ESCOBEDO et al., "Platelet-derived Growth Factor Receptors Expressed by cDNA Transfection Couple to a Diverse Group of Cellular Responses Associated With Cell Proliferation," <u>J. Biol. Chem.</u> , 263(3):1482-1487 (1988).			
	AP				ESCOBEDO et al., "A PDGF Receptor Domain Essential For Mitogenesis But Not For Many Other Responses to PDGF," <u>Nature</u> , 335:85-87 (1988).			
	AQ				ESCOBEDO et al., "A Common PDGF Receptor Is Activated By Homodimeric A and B Forms of PDGF," <u>Science</u> , 240:1532-1534 (1988).			
	AR				ESCOBEDO et al., "A Phosphatidylinositol-3 Kinase Binds to Platelet-Derived Growth Factor Receptors Through a Specific Receptor Sequence Containing Phosphotyrosine", <u>Molecular and Cellular Biology</u> , 11:1125-1132 (1991).			
	AS				FANTL et al., "Mutations of the Platelet-Derived Growth Factor Receptor that Cause a Loss of Ligand-Induced Conformational Change, Subtle Changes in Kinase Activity, and Impaired Ability to Stimulate DNS Synthesis," <u>Mol. Cell Biol.</u> , 9(10):4473-4478 (1989).			
	AT				FELDER et al., "Kinase Activity Controls the Sorting of the Epidermal Growth Factor Receptor Within the Multivesicular Body," <u>Cell</u> , 61:623-634 (1990).			
	AU				GIESE et al., "The Role of Individual Cysteine Residues in the Structure and Function of the v-sis Gene Product," <u>Science</u> , 236:1315-1318 (1987).			
	AV				GLENN et al., "Platelet-derived Growth Factor," <u>J. Biol. Chem.</u> , 257(9):5172-5172 (1982).			
	AW				GRAVES et al., "Evidence that a Human Osteosarcoma Cell Line Which Secretes a Mitogen Similar to Platelet-Derived Growth Factor Requires Growth Factors Present in Platelet-Poor Plasma," <u>Cancer Research</u> 43:83-87 (1983).			
	AX				GRONWALD et al., "Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: Evidence for more than one receptor class," <u>Proc. Nat'l Acad. Sci. USA</u> , 85:3435-3439 (1988).			
	AY				HART et al., "Synthesis, Phosphorylation, and Degradation of Multiple Forms of the Platelet-derived Growth Factor Receptor Studied Using a Monoclonal Antibody," <u>J. Biol. Chem.</u> , 262(22):10780-10785 (1987).			
	AZ				HART et al., "Two classes of PDGF Receptor Recognize Different Isoforms of PDGF," <u>Science</u> , 240:1529-1531 (1988).			
	BA				HART et al., "Expression of Secreted Human Immunoglobulin/PDGF-Receptor Fusion Proteins Which Demonstrate High Affinity Ligand Binding," <u>Miami Winter Cancer Symposium</u> (1989).			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3211343 v1

APR 17 2002

RECEIVED



Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Applicati n Number	10/027,400
				Filing Date	December 19, 2001
				First Named Invent r	Lewis Thomas Williams
				Group Art Unit	1646
				Examiner Name	Unassigned
				Attorney Docket Number	02307K-026726US
Sheet	3	of	6		

TECH CENTER 1600/2900

APR 17 2002

RECEIVED

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	AA				HAYNES et al., "Constitutive, long-term production of human interferons by hamster cells containing multiple copies of a cloned interferon gene," <u>Nucl. Acids Res.</u> , 11(3):687-706 (1983).		
	BC				HEIDARAN et al., "Chimeric α- and β-Platelet-derived Growth Factor (PDGF) Receptors Define Three Immunoglobulin-like Domains of the α-PDGF Receptor That Determine PDGF-AA Binding Specificity," <u>J. Biol. Chem.</u> , 265(31):18741-18744.		
	BD				HELDIN et al., "Interaction of Platelet-derived Growth Factor with Its Fibroblast Receptor," <u>J. Biol. Chem.</u> , 257(8):4216-4221 (1982).		
	BE				HELDIN et al., "Binding of different dimeric forms of PDGF to human fibroblasts evidence for two separate receptor types," <u>EMBO J.</u> , 7(5):1387-1393 (1988).		
	BF				HELDIN et al., "Dimerization of B-type Platelet-derived Growth Factor Receptors Occurs After Ligand Binding and Is Closely Associated With Receptor Kinase Activation," <u>J. Biol. Chem.</u> , 264(15):8905-8912 (1989).		
	BG				JACOBS et al., "Isolation and Characterization of Genomic and cDNA Clones of Human Erythropoietin," <u>Nature</u> 313:806-810 (1985).		
	BH				KAPLAN et al., "PDGF β-Receptor Stimulates Tyrosine Phosphorylation of GAP and Association of GAP with a Signaling Complex," <u>Cell</u> , 61:125-133 (1990).		
	BI				KAZLAUSKAS et al., "Different effects of homo- and heterodimers of platelet-derived growth factor A and B chains on human and mouse fibroblasts," <u>EMBO J.</u> , 7(12):3727-3735 (1988).		
	BJ				KAZLAUSKAS et al., "Phosphorylation of the PDGF Receptor β Subunit Creates a Tight Binding Site for Phosphatidylinositol 3 Kinase", <u>The EMBO Journal</u> , 9:3279-3286 (1990).		
	BK				KEATING et al., "Processing of the Platelet-derived Growth Factor Receptor," <u>J. Biol. Chem.</u> , 262(16):7932-7937 (1987).		
	BL				KEATING et al., "Autocrine Stimulation of Intracellular PDGF Receptors in v-si Transformed Cells," <u>Science</u> , 239:914-916 (1988).		
	BM				KEATING et al., "Ligand Activation Causes a Phosphorylation-dependent Change in Platelet-derived Growth Factor Receptor Conformation," <u>J. Biol. Chem.</u> , 263(26):12805-12808 (1988).		
	BN				KEATING et al., "Platelet-derived Growth Factor Receptor Inducibility is Acquired Immediately After Translation and Does Not Require Glycosylation," <u>J. Biol. Chem.</u> , 264(16):9129-9132 (1989).		
	BO				KIMBALL et al., "Epidermal Growth Factor (EGF) Binding to Membranes Immobilize in Microtiter Wells and Estimation of EGF-Related Transforming Growth Factor Activity," <u>Biochimica et Biophysica Acta</u> , 771:82-88 (1984).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3211343 v1



ORIGINALLY FILED

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/027,400
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 19, 2001
		First Named Inventor	Lewis Thomas Williams
		Group Art Unit	1646
		Examiner Name	Unassigned
		Attorney Docket Number	02307K-026726US
Sheet	4	of	6

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	BP				KORNBLUTH et al., "Novel Tyrosine Kinase Identified by Phosphotyrosine Antibodic Screening of cDNA Libraries," <u>Mol. Cell. Biol.</u> 8(12):5541-5544 (1988).		
	BQ				KYPTA et al., "Association between the PDGF Receptor and Members of the src Family of Tyrosine Kinases," <u>Cell</u> 62:481-492 (1990).		
	BR				MARX, "Oncogenes Evoke New Cancer Therapies," <u>Science</u> 249:1376-1378 (1990).		
	BS				MATSUI et al., "Isolation of a Novel Receptor cDNA Establishes the Existence of Two PDGF Receptor Genes," <u>Science</u> 243:800-804 (1989).		
	BT				MATSUI et al., "Independent expression of human α or β platelet-derived growth factor receptor cDNAs in a naïve hematopoietic cell leads to functional coupling with mitogenic and chemotactic signaling pathways," <u>Proc. Natl. Acad. Sci. USA</u> 86:8314-8318 (1989).		
	BU				MORAN et al., "Src homology region 2 domains direct protein-protein interactions in signal transduction," <u>Proc. Natl. Acad. Sci. USA</u> 87:8622-8626 (1990).		
	BV				MORRISON et al., "Direct Activation of the Serine/Threonine Kinase Activity of Raf-1 through Tyrosine Phosphorylation by the PDGF β -Receptor," <u>Cell</u> 58:649-6__ (1989).		
	BW				MORRISON et al., "Platelet-Derived Growth Factor (PDGF) - Dependent Association Phospholipase C- γ with the PDGF Receptor Signaling Complex," <u>Mol. Cell. Biol.</u> 10(5):2359-2366 (1990).		
	BX				NISHIBE et al., "Increase of the Catalytic Activity of Phospholipase C- γ 1 by Tyrosine Phosphorylation," <u>Science</u> 250:1253-1256 (1990).		
	BY				NISTER et al., "A Glioma-Derived PDGF A Chain Homodimer Has Different Function Activities from a PDGF AB Heterodimer Purified from Human Platelets," <u>Cell</u> 52:791-799 (1988).		
	BZ				ORCHANSKY et al., "Phosphatidylinositol Linkage of a Truncated Form of the Platelet-derived Growth Factor Receptor," <u>J. Biol. Chem.</u> 263(29):15159-15165 (1988).		
	CA				PERALTA et al., "Primary Structure and Biochemical Properties of an M ₂ Muscarinic Receptor," <u>Science</u> 236:600-605 (1987).		
	CB				QIU et al., "Primary Structure of <i>ckit</i> : relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of <i>v-kit</i> involves deletion of extracellular domain and C terminus," <u>EMBO J.</u> 7(4):1003-1011 (1988).		
	CC				REID et al., "Two forms of the basic fibroblast growth factor receptor-like mP are expressed in the developing mouse brain," <u>Proc. Natl. Acad. Sci. USA</u> 87:1596-1600 (1990).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3211343 v1

APR 17 2002

RECEIVED



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **5** of **6**

Complete if Known

Application Number	10/027,400
Filing Date	December 19, 2001
First Named Inventor	Lewis Thomas Williams
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	02307K-026726US

TECH CENTER 160012900

RECEIVED
APR 17 2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	CD				RONNSTRAND et al., "Purification of the Receptor for Platelet-derived Growth Factor from Porcine Uterus," <u>J. Biol. Chem.</u> , 262(7):2929-2932 (1987).			
	BE				ROUSSEL et al., "Transforming potential of the <i>c-fms</i> proto-oncogene (CSF-1 receptor)," <u>Nature</u> , 325:549-552 (1987).			
	BF				RUTA et al., "A novel protein tyrosine kinase gene whose expression is modulated during endothelial cell differentiation," <u>Oncogene</u> , 3:9-15 (1988).			
	BG				SEIFERT et al., "Two Different Subunits Associate to Create Isoform-specific Platelet-derived Growth Factor Receptors," <u>J. Biol. Chem.</u> , 264(15):8771-8778 (1989).			
	BH				SMITH et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen," <u>Science</u> , 238:1704-1707 (1987).			
	BI				ULLRICH et al., "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> , 61:203-212 (1990).			
	BJ				VAN DER SCHAAL et al., "An Enzyme-Linked Lectin Binding Assay for Quantitative Determination of Lectin Receptors," <u>Anal. Biochem.</u> , 140:48-55 (1984).			
	BK				VAN DRIEL et al., "Stoichiometric Binding of Low Density Lipoprotein (LDL) Monoclonal Antibodies to LDL Receptors in a Solid Phase Assay," <u>J. Biol. Chem.</u> , 264(16):9533-9538 (1989).			
	BL				WILLIAMS et al., "Platelet-derived growth factor binds specifically to receptors on vascular smooth muscle cells and the binding becomes nondissociable," <u>Proc. Nat'l Acad. Sci. USA</u> , 79:5867-5870 (1982).			
	BM				WILLIAMS et al., "Platelet-derived Growth Factor Receptors Form a High Affinity State in Membrane Preparations," <u>J. Biol. Chem.</u> , 259(8):5287-5294 (1984).			
	BN				WILLIAMS et al., "PDGF Receptors: Structural and Functional Studies," <u>Miami Winter Symposium, ICSU Short Reports</u> , 4:168-171 (1986).			
	BO				WILLIAMS et al., "The Stimulation of Paracrine and Autocrine Mitogenic Pathways by the Platelet-Derived Growth Factor Receptor," <u>J. Cell. Physiol. Suppl.</u> , 5:27-30 (1987).			
	BP				WILLIAMS, "Signal Transduction by the Platelet-Derived Growth Factor Receptor," <u>Science</u> , 243:1564-1570 (1989).			
	BQ				WILLIAMS et al., "The Immunoglobulin Superfamily - Domains for Cell Surface Recognition," <u>Ann. Rev. Immunology</u> , 6:381-405 (1988).			
	BR				WILLIAMS, "Stimulation of Paracrine and Autocrine Pathways of Cell Proliferation by Platelet-Derived Growth Factor," <u>Clinical Research</u> , 36(1):5-10 (1988).			


Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3211343 v1



COPY OF PAPERS
ORIGINALLY FILED

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

6

Complete if Known

Application Number	10/027,400
Filing Date	December 19, 2001
First Named Inventor	Lewis Thomas Williams
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	02307K-026726US

TECH CENTER 1600/2900

APR 17 2002

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	BS	WILLIAMS, "Signal Transduction by the Platelet-Derived Growth Factor Receptor Involves Association of the Receptor with Cytoplasmic Molecules," <u>Clinical Research</u> , 37:564-568 (1989).						
	BT	WILLIAMS et al., "Signal Transduction by the Platelet-Derived Growth Factor Receptor," <u>CSH Symp. Quant. Biol.</u> , 53:455-465 (1988).						
	BU	YARDEN et al., "Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors," <u>Nature</u> , 323:226-232 (1986).						
	BV	YARDEN et al., "Growth Factor Receptor Tyrosine Kinases," <u>Ann. Rev. Biochem.</u> , 57:443-478 (1988).						

PA 3211343 v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3211343 v1